| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
310,240,000 |
| Market
Cap: |
6.49(B) |
| Last
Volume: |
1,548,181 |
Avg
Vol: |
2,440,013 |
| 52
Week Range: |
$18.78 - $24.13 |
|
| Level
I Sector: |
Industrials |
| Level
II Sector: |
Diversified Services |
| Level
III Sector: |
Research Services |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : 14.9 |
| Insider 6 Months : 16.6 |
| Insider 3/6 Months : 32 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Exelixis is an oncology-focused biotechnology company that engages in the discovery, development and commercialization of new medicines for cancers. Co.'s products include: CABOMETYX® (cabozantinib) tablets approved for renal cell carcinoma, and for previously treated hepatocellular carcinoma; and COMETRIQ® (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. The other products are: COTELLIC® (cobimetinib), an inhibitor of MEK approved as part of a combination regimen to treat forms of melanoma; and MINNEBRO® (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved for the treatment of hypertension in Japan.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
190,000 |
310,409 |
310,409 |
310,409 |
| Total Buy Value |
$3,932,734 |
$6,534,772 |
$6,534,772 |
$6,534,772 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
2 |
2 |
2 |
| Total Shares Sold |
77,148 |
336,706 |
542,969 |
981,371 |
| Total Sell Value |
$1,703,116 |
$7,468,007 |
$11,664,525 |
$19,365,156 |
| Total People Sold |
3 |
5 |
6 |
10 |
| Total Sell Transactions |
3 |
9 |
13 |
25 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Morrissey Michael M |
President and CEO |
• • – |
2020-04-20 |
4 |
D |
$23.58 |
$3,605,877 |
D/D |
(152,921) |
173,064 |
|
- |
|
| Morrissey Michael M |
President and CEO |
• • – |
2020-04-20 |
4 |
OE |
$5.51 |
$1,322,400 |
D/D |
240,000 |
325,985 |
|
- |
|
| Scangos George A |
Director |
– • – |
2020-04-20 |
4 |
AS |
$23.39 |
$1,194,637 |
D/D |
(50,000) |
863,031 |
|
-8% |
|
| Haley Patrick J. |
EVP, Commercial |
• – – |
2020-04-20 |
4 |
AS |
$24.00 |
$120,000 |
D/D |
(5,000) |
116,873 |
|
-8% |
|
| Haley Patrick J. |
EVP, Commercial |
• – – |
2020-04-20 |
4 |
OE |
$1.70 |
$8,500 |
D/D |
5,000 |
121,873 |
|
- |
|
| Scangos George A |
Director |
– • – |
2020-04-15 |
4 |
AS |
$18.31 |
$457,750 |
D/D |
(25,000) |
913,031 |
|
19% |
|
| Scangos George A |
Director |
– • – |
2020-04-08 |
4 |
AS |
$18.35 |
$129,643 |
D/D |
(7,065) |
938,031 |
|
21% |
|
| Scangos George A |
Director |
– • – |
2020-04-07 |
4 |
AS |
$18.25 |
$299,939 |
D/D |
(16,435) |
945,096 |
|
29% |
|
| Lamb Peter |
EVP, Scientific Strategy & CSO |
• – – |
2020-04-06 |
4 |
AS |
$17.26 |
$863,000 |
D/D |
(50,000) |
126,531 |
|
24% |
|
| Lamb Peter |
EVP, Scientific Strategy & CSO |
• – – |
2020-04-06 |
4 |
OE |
$5.51 |
$275,500 |
D/D |
50,000 |
176,531 |
|
- |
|
| Wyszomierski Jack L |
Director |
– • – |
2020-04-03 |
4 |
AS |
$16.57 |
$229,461 |
D/D |
(13,848) |
161,678 |
|
32% |
|
| Wyszomierski Jack L |
Director |
– • – |
2020-04-03 |
4 |
OE |
$4.58 |
$226,200 |
D/D |
45,000 |
175,526 |
|
- |
|
| Scangos George A |
Director |
– • – |
2020-03-31 |
4 |
AS |
$18.06 |
$27,090 |
D/D |
(1,500) |
961,531 |
|
26% |
|
| Haley Patrick J. |
EVP, Commercial |
• – – |
2020-03-20 |
4 |
AS |
$15.37 |
$66,368 |
D/D |
(4,318) |
116,873 |
|
57% |
|
| Morrissey Michael M |
President and CEO |
• • – |
2020-03-09 |
4 |
GA |
$0.00 |
$0 |
I/I |
17,116 |
339,243 |
|
- |
|
| Morrissey Michael M |
President and CEO |
• • – |
2020-03-09 |
4 |
GD |
$0.00 |
$0 |
D/D |
17,116 |
85,985 |
|
- |
|
| Morrissey Michael M |
President and CEO |
• • – |
2020-03-04 |
4 |
D |
$19.89 |
$654,063 |
D/D |
(32,884) |
103,101 |
|
- |
|
| Morrissey Michael M |
President and CEO |
• • – |
2020-03-04 |
4 |
OE |
$5.51 |
$275,500 |
D/D |
50,000 |
135,985 |
|
- |
|
| Schwab Gisela Md |
Pres, Prod Dev & Med Aff & CMO |
• – – |
2020-03-04 |
4 |
S |
$19.20 |
$1,940,000 |
D/D |
(100,000) |
325,122 |
|
-20% |
|
| Schwab Gisela Md |
Pres, Prod Dev & Med Aff & CMO |
• – – |
2020-03-04 |
4 |
OE |
$1.70 |
$170,000 |
D/D |
100,000 |
425,122 |
|
- |
|
| Feldbaum Carl B |
Director |
– • – |
2020-03-03 |
4 |
S |
$18.41 |
$716,013 |
D/D |
(38,000) |
8,521 |
|
-27% |
|
| Feldbaum Carl B |
Director |
– • – |
2020-03-03 |
4 |
OE |
$4.58 |
$213,720 |
D/D |
38,000 |
46,521 |
|
- |
|
| Cohen Charles |
Director |
– • – |
2020-02-28 |
4 |
OE |
$4.58 |
$226,200 |
D/D |
45,000 |
65,979 |
|
- |
|
| Morrissey Michael M |
President and CEO |
• • – |
2020-02-26 |
4 |
AS |
$18.90 |
$472,850 |
D/D |
(25,000) |
85,985 |
|
16% |
|
| Morrissey Michael M |
President and CEO |
• • – |
2020-02-26 |
4 |
OE |
$5.51 |
$137,750 |
D/D |
25,000 |
110,985 |
|
- |
|
1421 Records found
|
|
Page 20 of 57 |
|
|
0.32 (1.51%) 
